2021

Hangartner L, Beauparlant D, Rakasz E, Nedellec R, Hozé N, McKenney K, Martins MA, Seabright GE, Allen JD, Weiler AM, Friedrich TC, Regoes RR, Crispin M, Burton DR. (2021) Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Sci Transl Med. 13(585):eabe3349. [REPRINT]

Burton DR, Topol EJ. (2021) Toward superhuman SARS-CoV-2 immunity? Nat Med. 27(1):5-6.

Burton DR, Topol EJ. (2021) Variant-proof vaccines – invest now for the next pandemic. Nature. 590(7846):386-388.

Burton DR. (2021) A new lease on life for an HIV-neutralizing antibody class and vaccine target. Proc Natl Acad Sci U S A. 118(7):e2026390118.

Conti S, Kaczorowski KJ, Song G, Porter K, Andrabi R, Burton DR, Chakraborty AK, Karplus M. (2021) Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site. Proc Natl Acad Sci U S A. 118(9):e2018338118.

Turman JM, Cheplowitz AM, Tiwari C, Thomas T, Joshi D, Bhat M, Wu Q, Pong E, Chu SY, Szymkowski DE, Sharma A, Seveau S, Robinson JM, Kwiek JJ, Burton DR, Rajaram MVS, Kim J, Hangartner L, Ganesan LP. (2021) Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis. J Immunol. 206(6):1284-1296.

Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, O’Brien CM, Brown ME, Geoghegan JC, Belk J, Peng L, Yang L, Hou Y, Scobey TD, Burton DR, Nemazee D, Dye JM, Voss JE, Gunn BM, McLellan JS, Baric RS, Gralinski LE, Walker LM. (2021) Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 371(6531):823-829.